Highlights on Prostate Cancer from Urological and Oncological Congresses in 2007

European Urology, Supplements

Volumn 7, Issue 6, 2008, Pages 460-476

  Mottet, Nicolas ^a   Schalken, Jack A ^b   Heidenreich, Axel ^c   Bastian, Patrick J ^d   Irani, Jacques ^e   Salomon, Laurent ^f   Soulié, Michel ^g  

^a Clinique Mutualiste   (France)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY OF COLOGNE   (Germany)

^d LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^e POITIERS UNIVERSITY HOSPITAL   (France)

^f HENRI MONDOR HOSPITAL   (France)

^g TOULOUSE UNIVERSITY HOSPITAL   (France)

Author keywords

Androgen deprivation therapy; Biopsy; Diagnosis; Hormone therapy; Hormone refractory prostate cancer; Imaging; Nomogram; Prostate cancer; Radical prostatectomy; Radiotherapy

Indexed keywords

ABIRATERONE; ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; BICALUTAMIDE; C REACTIVE PROTEIN; CALCITRIOL; CHOLINE C 11; DOCETAXEL; GEFITINIB; GOSERELIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IODINE 125; KETOCONAZOLE; MITOXANTRONE; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SATRAPLATIN; TOREMIFENE;

BONE DENSITY; BRACHYTHERAPY; CANCER LOCALIZATION; CANCER RELAPSE; CANCER SCREENING; CANCER SURVIVAL; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIARRHEA; DRUG MECHANISM; DRUG MEGADOSE; EDEMA; ELASTOGRAPHY; ERECTILE DYSFUNCTION; GLEASON SCORE; GRAY SCALE ECHOGRAPHY; HORMONAL THERAPY; HUMAN; HYPERTENSION; LOW DRUG DOSE; MEDICAL SOCIETY; METASTASIS; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; RASH; REVIEW; SENSITIVITY AND SPECIFICITY; SYNCOPE; URINE INCONTINENCE;

EID: 44549086744     PISSN: 15699056     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eursup.2008.01.004     Document Type: Review

References (77)

1. Jemal A., Siegel R., Ward E., et al. Cancer statistics, 2007. CA Cancer J Clin 57 (2007) 43-66
2. http://info.cancerresearchuk.org/cancerstats/types/prostate/incidence. Accessed 2007.
3. American Cancer Society. Cancer Statistics 2007. Available at: http://www.cancer.org/docroot/PRO/content/PRO_1_1_Cancer_Statistics_2007_Presentation.asp. Accessed 2007.
4. Hsing A.W., Tsao L., and Devesa S.S. International trends and patterns of prostate cancer incidence and mortality. Int J Cancer 85 (2000) 60-67
5. Delongchamps N.B., Singh A., and Haas G.P. The role of prevalence in the diagnosis of prostate cancer. Cancer Control 13 (2006) 158-168
6. Boyle P., and Ferlay J. Cancer incidence and mortality in Europe, 2004. Ann Oncol 16 (2005) 481-488
7. American Cancer Society. Cancer Facts & Figures. Available at URL: http://www.cancer.org/docroot/STT/content/STT_1x_Cancer_Facts__Figures_2007.asp. Accessed 2007.
8. Villers A., McNeal J.E., Freiha F.S., and Stamey T.A. Multiple cancers in the prostate. Morphologic features of clinically recognized versus incidental tumors. Cancer 70 (1992) 2313-2318
9. Epstein J.I., Walsh P.C., Carmichael M., and Brendler C.B. Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA 271 (1994) 368-374
10. Bastian P.J., Mangold L.A., Epstein J.I., and Partin A.W. Characteristics of insignificant clinical T1c prostate tumors; a contemporary analysis. Cancer 101 (2004) 2001-2005
11. Arndt B., Boudny P., Herfs G., et al. Validation of pretherapeutic criterias and nomograms for identifying insignificant prostate cancer. Eur Urol Suppl 6 (2007) 49 (abstract no. 107)
12. Buschemeyer III W.C., and Freedland S.J. Obesity and prostate cancer: epidemiology and clinical implications. Eur Urol 52 (2007) 331-343
13. Larré S., Cancel-Tassin G., Azzouzi A.R., et al. Influence of obesity on PSA levels on a screened population. Eur Urol Suppl 6 (2007) 177 (abstract no. 618)
14. Murtola T., Tammela T., Määttänen L., and Auvinen A. Prostate cancer and serum PSA among users of serum lipid-lowering drugs in the Finnish Prostate Cancer Screening Trial. Eur Urol Suppl 6 (2007) 223 (abstract no. 803)
15. Pallwein L., Friedrich A., Pallwein E., Mitterberger M., Bartsch G., and Frauscher F. Comparison of sonoelastography guided biopsy with systematic biopsy: impact on prostate cancer detection. Eur Urol Suppl 6 (2007) 196 (abstract no. 693)
16. Raber M., Scattoni V., Roscigno M., et al. Extended 24-sample TRUS prostatic needle biopsy protocol for prostate cancer detection as initial diagnostic strategy. Eur Urol Suppl 6 (2007) 197 (abstract no. 697)
17. Giannarini G., Mogorovich A., Valent F., et al. Continuing or discontinuing low-dose aspirin prior to transrectal prostate biopsy? Results of a prospective randomized trial. Eur Urol Suppl 6 (2007) 198 (abstract no. 703)
18. Seitz C., Palermo S., and Djavan B. Prostate biopsy. Minerva Urol Nefrol 55 (2003) 205-218
19. Bussemakers M.J., van Bokhoven A., Verhaegh G.W., Smit F.P., Karthaus H.F., Schalken J.A., et al. DD3: a new prostate-specific gene, highly overexpressed in prostate cancer. Cancer Res 59 (1999) 5975-5979
20. Hessels D., Klein Gunnewiek J.M.T., van Oort I., et al. DD3PCA3-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 44 (2003) 8-16
21. Groskopf J., Aubin S.M., Deras I.L., et al. APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer. Clin Chem 52 (2006) 1089-1095
22. Haese A., Van Poppel H., Marberger M., et al. The value of the PCA3 Assay in guiding decision which men with a negative prostate biopsy need immediate repeat biopsy: preliminary European data. Eur Urol Suppl 6 (2007) 48 (abstract no. 101)
23. Briganti A., Chun F.K.H., Da Pozzo L.F., et al. Lymph node invasion in prostate cancer patients with a PSA < 10 ng/mL: which patients deserve a pelvic lymph node dissection?. Eur Urol Suppl 6 (2007) 88 (abstract no. 263)
24. Heidenreich A., Ohlmann C.H., and Polyakov S. Anatomical extent of pelvic lymphadenectomy in patients undergoing radical prostatectomy. Eur Urol 52 (2007) 29-37
25. Martorana G., Schiavina R., Brunocilla E., et al. 11C-Choline-PET/CT for preoperative N-staging in high risk prostate cancer. Eur Urol Suppl 6 (2007) 89 (abstract no. 266)
26. Eschmann S.M., Schilling D., Pfannenberg C., et al. Clinical staging and re-staging in prostate cancer: comparison of 11C-Choline-PET/CT and whole body MRI. Eur Urol Suppl 6 (2007) 89 (abstract no. 267)
27. Zelhof B., Turnbull L., and Cooksey G. The accuracy of 3T MRI for staging prostate cancer pre-operatively. Eur Urol Suppl 6 (2007) 89 (abstract no. 268)
28. Vormola R., Ortega C., Montemurro F., et al. Correlation of 11C-choline PET and PSA values in patients with prostate cancer and biochemical relapse after primary treatments. J Clin Oncol 25 Suppl (2007) 253s (abstract no. 5073)
29. Ohlmann C., Pfister D., Thüer D., Wille S., Engelmann U.H., and Heidenreich A. 11C-coline-positron emission tomography/computerized tomography (C-PET/CT) for tumor localization of locally recurrent prostate cancer after radiation therapy. Eur Urol Suppl 6 (2007) 229 (abstract no. 825)
30. Heidenreich A., Pfister D., Thüer D., Wille S., and Engelmann U.H. Prognostic risk factors to predict final pathohistology in patients undergoing radical salvage prostatectomy for locally recurrent prostate cancer after radiation therapy. Eur Urol Suppl 6 (2007) 282 (abstract no. 1039)
31. Freedland S.J., Humphreys E.B., Mangold L.A., et al. Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy. JAMA 294 (2005) 433-439
32. Roemeling S., Gosselaar C., Wolters T., Roobol M.J., Bangma C.H., and Schröder F.H. Outcome of screen-detected prostate cancer patients who could have been considered for active surveillance. Eur Urol Suppl 6 (2007) 279 (abstract no. 1027)
33. Ciezki J.P., Reddy C.A., Kupelian P.A., et al. A comparison of overall and cause-specific survival among patients with low- and intermediate-risk prostate cancer treated with brachytherapy, external beam radiotherapy, or radical prostatectomy. J Clin Oncol 25 Suppl (2007) 266s (abstract no. 5126)
34. Huyghe E., Nohra J., Delavierre D., et al. Erectile function after brachytherapy for localised prostate cancer: long-term results. Eur Urol Suppl 6 (2007) 206 (abstract no. 736)
35. Bolla M., Gonzalez D., Warde P., et al. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin. N Engl J Med 337 (1997) 295-300
36. Bolla M., van Tienhoven G., de Reijke T.M., et al. Concomitant and adjuvant androgen deprivation (ADT) with external beam radiation (RT) for locally advanced prostate cancer: 6 months versus 3 years ADT-Results of the randomized EORTC Phase III trial 22961. J Clin Oncol 25 Suppl (2007) 238s (abstract no. 5014)
37. Pilepich M.V., Caplan R., Byhardt R.W., et al. Phase III trial of androgen suppression using goserelin in unfavorable-prognosis carcinoma of the prostate treated with definitive radiotherapy: report of Radiation Therapy Oncology Group Protocol 85-31. J Clin Oncol 15 (1997) 1013-1021
38. Souhami L., Bae K., Pilepich V., and Sandler H. The impact of the duration of adjuvant hormonal therapy in patients with unfavorable prognosis prostate cancer treated with radiotherapy: Secondary analysis of RTOG 85-31. J Clin Oncol 25 Suppl (2007) 250s (abstract no. 5062)
39. Hernandez D.J., Nielsen M.E., Chuang A.-Y., et al. Cancer control following radical prostatectomy in men with capsular incision. J Urol 177 Suppl (2007) 249-250 (abstract no. 744)
40. Chuang A.Y., Nielsen M.E., Hernandez D.J., Walsh P.C., and Epstein J.I. The significance of positive surgical margin in areas of capsular incision in otherwise organ confined disease at radical prostatectomy. J Urol 178 (2007) 1306-1310
41. Boorjian S.A., Thompson R.H., Siddiqui S.A., Bagniewski S.M., Frank I., and Blute M.L. long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the PSA era. J Urol 177 Suppl (2007) 242-243 (abstract no. 723)
42. Boorjian S.A., Thompson R.H., Siddiqui S., Bagniewski S., Bergstralh E.J., Karnes R.J., et al. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol 178 (2007) 864-870
43. Porter C., Walz J., Gallina A., et al. Natural history of biochemical recurrence after radical prostatectomy for prostate cancer. Eur Urol Suppl 6 (2007) 181 (abstract no. 634)
44. Gaston K.E., Spiess P.E., Frey K., Urbauer D.L., and Pisters L.L. Salvage prostatectomy in the modern PSA era: the M.D. Anderson experience. J Urol 177 Suppl (2007) 590 (abstract no. 1775)
45. Blana A., Thüroff S., Murat F.J., Walter B., Chaussy C., and Gelet A. Long-term results with high intensity focused ultrasound (HIFU) in 140 patients with localized prostate cancer. Eur Urol Suppl 6 (2007) 199 (abstract no. 708)
46. Alivizatos G., and Skolarikos A. Incontinence and erectile dysfunction following radical prostatectomy: a review. ScientificWorldJournal 5 (2005) 747-758
47. Guimaraes M., Soares A., Reis F., et al. Treatment of male stress urinary incontinence with the bone-anchored perineal sling. Eur Urol Suppl 6 (2007) 74 (abstract no. 205)
48. Hage B., Hanna S., Schnutz G., Carmel M., Ponsot Y., and Tu L.M. Male sling for moderate to severe stress urinary incontinence: efficacy and mechanism. Eur Urol Suppl 6 (2007) 74 (abstract no. 206)
49. Verrini G., Borelli A., De Luca G., et al. The use of InVance, the male sling system, in patients with stress urinary incontinence (SUI) post radical prostatectomy (RP): 1 year follow-up. Eur Urol Suppl 6 (2007) 74 (abstract no. 208)
50. D'Ancona C., Reges R., Palma P., Riccetto C., and Netto Jr. N.R. Evaluation of male sling and health related quality of life for stress urinary incontinence: are the long term results maintained?. Eur Urol Suppl 6 (2007) 73 (abstract no. 204)
51. Kocjancic E., Crivellaro S., Ranzoni S., and Frea B. Surgical treatment of male urodynamic stress urinary incontinence: adjustable continence therapy. Eur Urol Suppl 6 (2007) 75 (abstract no. 211)
52. Hampel C., Gillitzer R., Wiesner C., and Thüroff J.W. Complication management and risk factors of the ProACT system for treatment of male stress incontinence. Eur Urol Suppl 6 (2007) 75 (abstract no. 212)
53. Studer U.E., Whelan P., Albrecht W., et al. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol 24 (2006) 1868-1876
54. Studer U.E., Collette L., Whelan P., et al. Which subgroups of patients with newly diagnosed T0-4 N0-2 M0 prostate cancer not suitable for local treatment with curative intent (EORTC 30891) are at risk to die from prostate cancer and benefit from immediate androgen deprivation?. Eur Urol Suppl 6 (2007) 27 (abstract no. 19)
55. Gallina A., Karakiewicz P.I., Walz J., et al. Increased risk of newly diagnosed comorbidities in prostate cancer patients treated with androgen deprivation therapy. J Urol 177 Suppl (2007) 200 (abstract no. 598)
56. Mottet N., Prayer-Galetti T., Hammerer P., Kattan M.W., and Tunn U. Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer. BJU Int 98 (2006) 20-27
57. Mitlak B.H., and Cohen F.J. Selective estrogen receptor modulators: a look ahead. Drugs 57 (1999) 653-663
58. Smith M.R., Chu F., Forrest J., et al. Phase III interim analysis demonstrates toremifene increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol 177 Suppl (2007) 335 (abstract no. 1015)
59. Bhandari M.S., Crook J., and Hussain M. Should intermittent androgen deprivation be used in routine clinical practice?. J Clin Oncol 23 (2005) 8212-8218
60. Miller K., Steiner A., Lingnau A., et al. Randomised prospective study of intermittent versus continuous androgen suppression in advanced prostate cancer. J Clin Oncol 25 Suppl (2007) 238s (abstract no. 5015)
61. Messing E.M., Manola J., Yao J., et al. Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol 7 (2006) 472-479
62. Wong Y., Freedland S., Hudes G., Mitra N., Montagnet C., and Armstrong K. Androgen deprivation therapy (ADT) for node positive prostate cancer. J Clin Oncol 25 Suppl (2007) 250s (abstract no. 5061)
63. Byar D.P. Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate. Cancer 32 (1973) 1126-1130
64. The medical research council prostate working party investigators group. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. BJU International 1997;79:235-46.
65. Wadhwa V., Weston R., and Parr N. A large proportion of patients with advanced prostate cancer continue to die of non-cancer causes after 5 years follow-up. Eur Urol Suppl 6 (2007) 87 (abstract no. 259)
66. Petrylak D.P., Tangen C.M., Hussain M.H., et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N Engl J Med 351 (2004) 1513-1520
67. Tannock I.F., de Wit R., Berry W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004) 1502-1512
68. Eisenberger M., Garrett-Mayer E.S., Yang Y.O., de Wit R., Tannock I., and Armstrong A.J. A multivariate prognostic nomogram incorporating PSA kinetics in hormone-refractory metastatic prostate cancer (HRPC). J Clin Oncol 25 Suppl (2007) 249s (abstract no. 5058)
69. Beer T.M., Ryan C.W., Venner P.M., et al. Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol 25 (2007) 669-674
70. Graff J., Lalani A.S., Lee S., et al. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer (AIPC): Results from the ASCENT trial. J Clin Oncol 25 Suppl (2007) 253s (abstract no. 5074)
71. Aus G., Abbou C.C., Bolla M., et al. EAU guidelines on prostate cancer. Eur Urol 48 (2005) 546-551
72. Sternberg C.N., Petrylak D., Witjes F., et al. Satraplatin (S) demonstrates significant clinical benefits for the treatment of patients with HRPC: results of a randomized phase III trial. J Clin Oncol 25 Suppl (2007) 239s (abstract no. 5019)
73. Attard G., Belldegrun A.S., and de Bono J.S. Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer. BJU Int 96 (2005) 1241-1246
74. Attard G., Yap T.A., Reid A.H., et al. Phase I study of continuous oral dosing of an irreversible CYP17 inhibitor, abiraterone (A), in castration refractory prostate cancer (CRCP) patients (p) incorporating the evaluation of androgens and steroid metabolites in plasma and tumor. J Clin Oncol 25 Suppl (2007) 250s (abstract no. 5063)
75. Ryan C.J., Rosenberg J., Lin A., Valiente J., Kime J., and Small E.J. Phase I evaluation of abiraterone acetate (CB7630), a 17 alpha hydroxylase C17,20-Lyase inhibitor in androgen-independent prostate cancer (AiPC). J Clin Oncol 25 Suppl (2007) 250s (abstract no. 5064)
76. Canil C.M., Moore M.J., Winquist E., et al. Randomized phase II study of two doses of gefitinib in hormone-refractory prostate cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group. J Clin Oncol. 23 (2005) 455-460
77. Boccardo F., Rubagotti A., Tacchini L., et al. Gefinitib (G) plus prednisone (P) versus placebo (pl) plus prednisone in the treatment of hormone-refractory prostate cancer (HRPC): a randomized phase II trial. J Clin Oncol 25 Suppl (2007) 252s (abstract no. 5070)